STAT+ convened independent gene editing experts to review decision-making around Huidagene’s muscle gene editing trial after the death of a young boy. The analysis revisited actions taken months earlier, including early data presentation at the American Society for Gene and Cell Therapy (ASGCT) Presidential Symposium. Experts consulted by STAT+ were divided on the quality of the company’s science and the reasoning behind the trial approach. The report underscores how preclinical rigor, translational judgment and trial governance are being re-evaluated in gene editing following serious adverse outcomes. For the cell and gene therapy community, the case functions as another pressure point on clinical risk management, including how safety signals and uncertainty are handled as programs move from early presentations to human dosing.